Staging versus Biology in Breast Cancer
Kathy S. Albain, MD, discusses staging versus biology in breast cancer.
Kathy S. Albain, MD, medical oncologist, Loyola University Chicago, professor, Stritch School of Medicine, director, Breast Clinical Research Program, Thoracic Oncology Research Program, Cardinal Bernardin Cancer Center, discusses staging versus biology in breast cancer.
Clinical Pearls
- When patients have high-stage disease signified by many positive nodes, larger tumor, or aggressive biologic features, a physician’s decision is more straightforward
- When a patient’s stage of disease, tumor volume or disease burden is high but the biology of the cancer appears to be favorable or when a patient with small tumors has an aggressive or unfavorable biology, it is more challenging for a physician to decide on treatment
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
